1921
Volume 75, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Australian mosquitoes from which Japanese encephalitis virus (JEV) has been recovered (, , and ) were assessed for their ability to be infected with the ChimeriVax™-JE vaccine, with yellow fever vaccine virus 17D (YF 17D) from which the backbone of ChimeriVax™-JE vaccine is derived and with JEV-Nakayama. None of the mosquitoes became infected after being fed orally with 6.1 log plaque-forming units (PFU)/mL of ChimeriVax™-JE vaccine, which is greater than the peak viremia in vaccinees (mean peak viremia = 4.8 PFU/mL, range = 0–30 PFU/mL of 0.9 days mean duration, range = 0–11 days). Some members of all three species of mosquito became infected when fed on JEV-Nakayama, but only was infected when fed on YF 17D. The results suggest that none of these three species of mosquito are likely to set up secondary cycles of transmission of ChimeriVax™-JE in Australia after feeding on a viremic vaccinee.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2006.75.659
2006-10-01
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/75/4/0750659.html?itemId=/content/journals/10.4269/ajtmh.2006.75.659&mimeType=html&fmt=ahah

References

  1. Tsai TF, 1994. Japanese encephalitis vaccines. Plotkin SA, Mortimer EA, eds. Vaccines. Second edition. Philadelphia: W.B. Saunders, 671–713.
  2. Chambers TJ, Nestorowicz A, Mason PW, Rice CM, 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 73 : 3095–3101.
  3. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P, 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax™-JE): Phase II clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188 : 1213–1230.
  4. Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, Guirakhoo F, 2002. Clinical proof of principle for Chimeri Vax™: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20 : 1004–1018.
  5. Whitman L, 1939. Failure of Aedes aegypti to transmit yellow fever cultured virus (17D). Am J Trop Med 19 : 19–26.
  6. Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR, 2000. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax™-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus and Aedes aegypti mosquitoes. Am J Trop Med Hyg 62 : 480–484.
  7. Ritchie SA, Phillips D, Broom A, Mackenzie J, Poidinger M, van den Hurk A, 1997. Isolation of Japanese encephalitis virus from Culex annulirostris in Australia. Am J Trop Med Hyg 56 : 80–84.
  8. Johansen CA, van den Hurk AF, Ritchie SA, Zborowski P, Nisbet DJ, Paru R, Bockarie MJ, Macdonald J, Drew AC, Khromykh TI, Mackenzie JS, 2000. Isolation of Japanese encephalitis virus from mosquitoes (Diptera: Culicidae) collected in the Western Province of Papua New Guinea, 1997–1998. Am J Trop Med Hyg 62 : 631–638.
  9. Johansen CA, van den Hurk AF, Pyke AT, Zborowski P, Phillips DA, Mackenzie JS, Ritchie SA, 2001. Entomological investigation of an outbreak of Japanese encephalitis virus in the Torres Strait, Australia in 1998. J Med Entomol 38 : 581–588.
  10. van den Hurk AF, Nisbet DJ, Hall RA, Kay BH, Mackenzie JS, Ritchie SA, 2003. Vector competence of Australian mosquitoes (Diptera: Culicidae) for Japanese encephalitis virus. J Med Entomol 40 : 82–90.
  11. Karabatsos N, Buckley SM, 1967. Susceptibility of the baby-hamster kidney-cell line (BHK-21) to infection with Arboviruses. Am J Trop Med Hyg 16 : 99–105.
  12. Rhim JS, Schell K, Creasy B, Case W, 1969. Biological characteristics and viral susceptibility of an African green monkey kidney cell line (Vero). Proc Soc Exp Biol Med 132 : 670–678.
  13. Gorman BM, Leer JR, Filippich C, Goss PD, Doherty RL, 1975. Plaquing and neutralisation of arboviruses in the PS-EK line of cells. Aust J Med Tech 6 : 65–71.
  14. Rosen L, Gubler D, 1974. The use of mosquitoes to detect and propagate dengue viruses. Am J Trop Med Hyg 23 : 1153–1160.
  15. Hardy JL, 1988. Susceptibility and resistance of vector mosquitoes. Monath TP, ed. The Arboviruses: Ecology and Epidemiology. Volume 1. Boca Raton, FL: CRC Press. 87–126.
  16. Johnson BW, Chambers TV, Crabtree MB, Arroyo J, Monath TP, Miller BR, 2003. Growth characteristics of the veterinary vaccine candidate ChimeriVax™-West Nile (WN) virus in Aedes and Culex mosquitoes. Med Vet Entomol 17 : 235–243.
  17. Johnson BW, Chambers TV, Crabtree MB, Bhatt TR, Guirakhoo F, Monath TP, Miller BR, 2002. Growth characteristics of ChimeriVax™-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes. Am J Trop Med Hyg 67 : 260–265.
  18. Johnson BW, Chambers TV, Crabtree MB, Guirakhoo F, Monath TP, Miller BR, 2004. Analysis of the replication kinetics of the ChimeriVax™-DEN 1,2,3,4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 70 : 89–97.
  19. World Health Organization, 1998. Requirements for yellow fever vaccine (requirements for biological substances no. 3, revised 1995). World Health Organ Tech Rep Ser 872 : 517–537.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2006.75.659
Loading
/content/journals/10.4269/ajtmh.2006.75.659
Loading

Data & Media loading...

  • Received : 27 Mar 2006
  • Accepted : 04 Jun 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error